PARK19 is an autosomal recessive form of early-onset Parkinson's disease caused by biallelic loss-of-function mutations in the DNAJC6 gene (also known as auxilin-2). This form of PD is characterized by onset typically before age 30, rapid progression, and generally good response to levodopa therapy 1 2. DNAJC6-related PD represents one of the rarer monogenic forms of parkinsonism, accounting for a small percentage of early-onset cases.
The identification of DNAJC6 as a PD-causing gene highlights the importance of synaptic vesicle cycling in dopaminergic neuron survival. Unlike other PARK genes involved in mitochondrial quality control (PARK2/Parkin, PINK1) or protein aggregation (SNCA, GBA), DNAJC6 mutations disrupt the fundamental process of synaptic vesicle endocytosis 3 4.
The link between DNAJC6 and Parkinson's disease was first established through genetic studies of consanguineous families with early-onset parkinsonism. Initial reports in 2012 by Edvardson et al. described homozygous mutations in DNAJC6 in patients with juvenile-onset PD 5. Subsequent studies have identified additional pathogenic variants and refined our understanding of the phenotype.
- PARK19: Numerical designation in the PARK gene nomenclature system
- DNAJC6: DnaJ heat shock protein family (Hsp40) member C6
- Auxilin-2: Originally named for its similarity to auxilin-1 (DNAJC5), involved in synaptic vesicle recycling
| Attribute | Value |
|-----------|-------|
| Gene | DNAJC6 |
| Previous Symbol | Auxilin-2 |
| Inheritance | Autosomal recessive |
| Chromosome | 19q13.43 |
| OMIM | OMIM: 613335 |
| Protein | Auxilin-2 (Hsp40 co-chaperone) |
| Protein Family | DnaJ/Hsp40 chaperone family |
| Exon Count | 20 exons |
| Transcript Length | 3.8 kb coding sequence |
¶ Gene Structure and Function
The DNAJC6 gene encodes a protein of 1,128 amino acids with several functional domains:
- N-terminal J domain: Binds Hsc70 and stimulates its ATPase activity
- Central region: Contains clathrin-binding motifs
- C-terminal region: Phosphorylation sites and regulatory elements
The J domain is essential for the co-chaperone function, while the clathrin-binding regions direct the protein to sites of synaptic vesicle endocytosis 6.
| Variant |
Type |
Effect |
First Identified |
Population |
| p.Leu275Pro |
Missense |
Loss of function |
Koh et al., 2014 |
Korean |
| p.Gly849Arg |
Missense |
Loss of function |
Edvardson et al., 2012 |
Palestinian |
| c.801-1G>A |
Splicing |
Loss of function |
Elsayed et al., 2016 |
Egyptian |
| p.Arg363* |
Nonsense |
Truncated protein |
Zhang et al., 2021 |
Chinese |
| p.Arg519His |
Missense |
Loss of function |
Olavarría et al., 2019 |
Chilean |
| Exon deletions |
Large deletion |
Loss of function |
Multiple families |
Various |
| c.2389+1G>A |
Splicing |
Loss of function |
Local et al., 2018 |
Turkish |
Pathogenic variants in DNAJC6 are predominantly loss-of-function mutations:
- Nonsense mutations create premature termination codons
- Splicing mutations disrupt mRNA processing
- Missense mutations impair protein function
- Large deletions remove critical protein domains
DNAJC6 pathogenic variants are rare in the general population. Carrier frequency estimates suggest:
- European descent: ~1 in 500-1,000
- East Asian: ~1 in 1,000-2,000
- Middle Eastern: Higher due to consanguinity 7 8
- Early onset: Typically before age 30, often in adolescence or early adulthood
- Rapid progression: Early development of motor complications compared to idiopathic PD
- Good levodopa response: Patients respond well to dopaminergic therapy
- Typical PD signs: Resting tremor, bradykinesia, rigidity, postural instability
- Parkinsonism asymmetry: Often begins asymmetrically 9
- Cognitive impairment: Variable; some patients develop dementia
- Psychiatric symptoms: Depression, anxiety, and behavioral changes
- Sleep disorders: REM sleep behavior disorder (RBD) in some cases
- Autonomic dysfunction: Constipation, orthostatic hypotension
- Olfactory dysfunction: Variable; not universal
| Phenotype |
Features |
Frequency |
| Juvenile PD |
Onset <20 years |
~40% |
| Early-onset PD |
Onset 20-40 years |
~60% |
| Atypical features |
Dystonia, myoclonus |
~25% |
While the core phenotype is consistent, significant variability exists:
- Age of onset can range from 12 to 45 years
- Some patients present with dystonia as the initial symptom
- Tremor-dominant and postural instability/gait difficulty subtypes both occur
- Cognitive decline may or may not develop
DNAJC6/Auxilin-2 has two key functions that, when disrupted, lead to neurodegeneration 10 11:
DNAJC6 is a neuronal co-chaperone that assists Hsc70 (heat shock cognate 70) in clathrin-mediated endocytosis. Loss of function impairs synaptic vesicle recycling, leading to:
- Depletion of synaptic vesicle pools
- Impaired dopamine release
- Accumulation of clathrin-coated intermediates
- Secondary mitochondrial dysfunction
flowchart TD
A["Synaptic Vesicle<br/>Release"] --> B["Clathrin Coat<br/>Assembly"]
B --> C["DNAJC6 + Hsc70<br/>Clathrin Uncoating"]
C --> D["Recycled Vesicle<br/>Ready for Release"]
E["DNAJC6 Mutation"] --> F["Impaired Uncoating"]
F --> G["Synaptic Vesicle<br/>Pool Depletion"]
G --> H["Dopamine Release<br/>Deficiency"]
H --> I["Dopaminergic<br/>Neuron Death"]
style I fill:#ffcdd2
The synaptic vesicle cycle involves several critical steps:
- Clathrin-mediated endocytosis: Formation of clathrin-coated vesicles
- Coat assembly: Clathrin triskelion polymerization
- Uncoating: DNAJC6/Hsc70-mediated clathrin removal
- Reacidification: V-ATPase restores proton gradient
- Reloading: Dopamine transported into vesicles
DNAJC6 acts specifically at the uncoating step, making it essential for rapid vesicle recycling 12.
The synaptic vesicle recycling defect leads to secondary mitochondrial impairment:
- Increased energy demands from failed vesicle recycling
- Calcium dysregulation at synapses
- Enhanced vulnerability to oxidative stress
- Impaired mitophagy due to energy depletion
Mitochondrial dysfunction in DNAJC6-related PD is secondary to the primary synaptic defect, distinguishing it from primary mitochondrial PD genes like PINK1 and Parkin.
Beyond synaptic vesicle cycling, DNAJC6 loss affects cellular protein quality control:
- Impaired chaperone function affects misfolded protein clearance
- Synaptic proteins may aggregate due to improper processing
- Endoplasmic reticulum stress response activation
Recent research has revealed an important interaction between DNAJC6 and LRRK2 (leucine-rich repeat kinase 2), another major PD-causing gene 13:
- LRRK2 phosphorylates auxilin at specific serine residues
- This phosphorylation regulates auxilin's interaction with clathrin
- LRRK2 mutations associated with PD may impair this regulation
- Suggests common pathway convergence
This interaction provides a mechanistic link between two major genetic causes of PD and suggests potential shared therapeutic targets.
| Gene |
Primary Function |
Pathway |
Typical Pathology |
| DNAJC6 |
Synaptic vesicle recycling |
Endocytosis |
Lewy bodies |
| PRKN (Parkin) |
Mitochondrial quality control |
Mitophagy |
Variable Lewy bodies |
| PINK1 |
Mitochondrial surveillance |
Mitophagy |
Lewy bodies |
| SNCA |
Synaptic function |
Protein aggregation |
Lewy bodies |
| LRRK2 |
Membrane trafficking |
Kinase signaling |
Lewy bodies |
- Age at onset <40 years
- Progressive parkinsonism with bradykinesia + at least one other sign
- Levodopa responsiveness
- Family history consistent with autosomal recessive inheritance
- Exclusion of secondary causes
| Step |
Test |
Purpose |
| 1 |
Neurological examination |
Document parkinsonism |
| 2 |
DaTscan |
Confirm dopaminergic deficit |
| 3 |
MRI brain |
Rule out structural causes |
| 4 |
Genetic testing |
Confirm DNAJC6 mutation |
| Method |
Detection Rate |
Comments |
| Panel sequencing |
60-70% |
Most common first test |
| Whole exome sequencing |
70-80% |
Broader detection |
| Whole genome sequencing |
~80% |
Detects intronic variants |
| Deletion/duplication analysis |
10-15% |
Important for exon deletions |
- PARK2 (Parkin): Similar early onset, but typically lacks Lewy bodies
- PINK1: Often has earlier onset, sleep benefit
- ATP13A2 (PARK9): More severe, includes dementia
- FBXO7: Often has pyramidal signs
- Idiopathic PD: Later onset, different progression
| Treatment |
Efficacy |
Notes |
| Levodopa/Carbidopa |
Excellent |
First-line; early benefit |
| Dopamine agonists |
Good |
Pramipexole, ropinirole |
| MAO-B inhibitors |
Moderate |
Selegiline, rasagiline |
| COMT inhibitors |
Adjunct |
Entacapone for wearing-off |
Treatment of DNAJC6-related PD follows standard PD protocols but with some specific considerations 14 15:
Motor Complications:
- Earlier development of dyskinesias compared to idiopathic PD
- Lower threshold for dyskinesia management
- May require fractionated dosing
Non-Motor Symptoms:
- Psychiatric symptoms: SSRIs, careful antipsychotic selection
- Sleep disorders: Melatonin, clonazepam for RBD
- Constipation: Fiber, laxatives, hydration
No disease-modifying therapies are specifically approved for PARK19, but several strategies are under investigation:
- AAV-mediated gene therapy: Deliver functional DNAJC6
- Small molecule co-chaperone activators: Enhance residual function
- Antioxidants: Combat secondary mitochondrial dysfunction
- Synaptic vesicle modulators: Improve vesicle cycling
- LRRK2 inhibitors: If LRRK2 interaction is relevant
- Patient-derived iPSCs: Dopaminergic neurons with DNAJC6 mutations show impaired synaptic vesicle trafficking and increased sensitivity to oxidative stress
- Knockdown systems: siRNA-mediated DNAJC6 depletion reproduces key phenotypes
- CRISPR models: Gene editing to introduce known pathogenic variants
- C. elegans: Knockout shows dopamine neuron degeneration
- Drosophila: Models recapitulate motor deficits
- Mouse: Conditional knockout under development
PARK19 is one of the rarer monogenic forms of PD:
| Population |
Estimated % of EOPD |
| Worldwide |
0.5-1.0% |
| Middle East |
2-3% (consanguinity) |
| Specific cohorts |
Up to 4% in juvenile PD |
- Autosomal recessive: both copies must be mutated
- Each parent is typically a heterozygous carrier
- 25% risk for each pregnancy
- Siblings of affected individuals: 25% affected, 50% carriers
- Explain autosomal recessive inheritance
- Discuss carrier testing for at-risk family members
- Review reproductive options (prenatal testing, preimplantation)
- Address psychological impact of genetic diagnosis
- What determines the age of onset variability?
- Why do some patients develop cognitive impairment?
- Can disease progression be slowed with early intervention?
- What is the precise mechanism of LRRK2-auxilin interaction?
- Gene replacement: AAV vectors carrying functional DNAJC6
- Protein aggregation inhibitors: Targeting secondary protein aggregation
- Synaptic function enhancers: Improving vesicle cycling
- Combination approaches: Multiple targets for synergistic effects
- DNAJC6 - The causative gene
- LRRK2 - Interacting protein
- DNAJC5 - Auxilin-1, related protein
- PARK2 - Other early-onset PD gene
- PINK1 - Mitochondrial PD gene